Efficacy and safety Of artemether‑lumefantrine for the treatment Of uncomplicated malaria and prevalence Of Pfk13 and Pfmdr1 polymorphisms After a decade of using artemisinin‑based Combination therapy in mainland Tanzania
| dc.contributor.author | Ishengoma, D.S. | |
| dc.contributor.author | Mandara, C.I. | |
| dc.contributor.author | Francis, F. | |
| dc.contributor.author | Talundzic, E. | |
| dc.contributor.author | Lucchi, N.W. | |
| dc.contributor.author | Ngasala, B. | |
| dc.contributor.author | Kabanywanyi, A.M. | |
| dc.contributor.author | Mahende, M.K. | |
| dc.contributor.author | Kamugisha, E. | |
| dc.contributor.author | Kavishe, R.A. | |
| dc.contributor.author | Muro, F. | |
| dc.contributor.author | Mohamed, A. | |
| dc.contributor.author | Mandike, R. | |
| dc.contributor.author | Mkude, S. | |
| dc.contributor.author | Chacky, F. | |
| dc.contributor.author | Paxton, L. | |
| dc.contributor.author | Greer, G. | |
| dc.contributor.author | Kitojo, C.A. | |
| dc.contributor.author | Njau, R. | |
| dc.contributor.author | Martin, T. | |
| dc.contributor.author | Venkatesan, M. | |
| dc.contributor.author | Warsame, M. | |
| dc.contributor.author | Halsey, E.S. | |
| dc.contributor.author | Udhayakumar, V. | |
| dc.date.accessioned | 2019-08-22T06:11:08Z | |
| dc.date.available | 2019-08-22T06:11:08Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | The World Health Organization recommends regular therapeutic efficacy studies (TES) to monitor the performance of first and second-line anti-malarials. In 2016, efficacy and safety of artemether-lumefantrine (AL) for the treatment of uncomplicated falciparum malaria were assessed through a TES conducted between April and October 2016 at four sentinel sites of Kibaha, Mkuzi, Mlimba, and Ujiji in Tanzania. The study also assessed molecular markers of artemisinin and lumefantrine (partner drug) resistance. | en_US |
| dc.identifier.citation | Ishengoma, D.S., Mandara, C.I., Francis, F., Talundzic, E., Lucchi, N.W., Ngasala, B., Kabanywanyi, A.M., Mahende, M.K., Kamugisha, E., Kavishe, R.A. and Mohamed, A., 2019. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malaria journal, 18(1), p.88. | en_US |
| dc.identifier.uri | http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/2406 | |
| dc.language.iso | en | en_US |
| dc.publisher | BMC | en_US |
| dc.relation.ispartofseries | ;18(1), p.88. | |
| dc.subject | Efficacy, | en_US |
| dc.subject | Safety, | en_US |
| dc.subject | Artemether-lumefantrine, | en_US |
| dc.subject | Falciparum malaria, | en_US |
| dc.subject | Tanzania | en_US |
| dc.title | Efficacy and safety Of artemether‑lumefantrine for the treatment Of uncomplicated malaria and prevalence Of Pfk13 and Pfmdr1 polymorphisms After a decade of using artemisinin‑based Combination therapy in mainland Tanzania | en_US |
| dc.type | Article | en_US |